Spruce Biosciences filings document the regulatory, financing and governance record of a late-stage biopharmaceutical company developing TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB). Form 8-K disclosures cover material agreements, including loan and security arrangements, at-the-market equity sale agreements, collaboration and license matters, and furnished clinical data updates related to the TA-ERT program.
Proxy materials describe shareholder voting matters, director elections, board committee changes, executive compensation and equity incentive plan matters. The filing record also includes capital-structure disclosures tied to common stock, equity awards, financing arrangements, risk factors and public-company governance.
Quartel Adrian W reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences’ Chief Medical Officer Adrian W. Quartel reported a grant of 13,000 Restricted Stock Units (RSUs) on July 27, 2026. Each RSU represents one share of common stock. The award vests 25% on June 15 of each year from 2027 through 2030, subject to his continuous service, resulting in direct holdings of 13,000 RSUs.
SPRUCE BIOSCIENCES, INC. submitted an initial insider ownership report for Adrian W. Quartel, who serves as Chief Medical Officer. The Form 3 lists no transactions or holdings for him and notes an accompanying Exhibit 24 labeled Power of Attorney.
Spruce Biosciences, Inc. has a significant shareholder group led by AIGH Capital Management LLC and related entities and person Orin Hirschman. These reporting persons collectively report beneficial ownership of 250,000 shares of Spruce Biosciences common stock, representing 9.1% of the outstanding class.
The reporting persons state they have sole voting power and sole dispositive power over 250,000 shares, with no shared voting or dispositive power. The ownership is reported jointly by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr. Hirschman, who is managing member or president of the investment entities.
Spruce Biosciences, Inc. appointed Adrian Quartel, M.D., FFPM as Chief Medical Officer on July 27, 2026, replacing Interim Chief Medical Officer Dr. Kirk Ways, who remains on the Board of Directors. Quartel has more than 25 years of international pharmaceutical experience across clinical development, pharmacovigilance, and medical affairs.
He previously served as Chief Medical Officer at Zevra Therapeutics, Acer Therapeutics, and Adamas Pharmaceuticals. Earlier, at BioMarin Pharmaceutical, he led global medical affairs and helped launch six treatments for rare diseases and genetic disorders, including the enzyme replacement therapies NAGLAZYME and Brineura. Quartel holds an M.D. from Erasmus University Medical School and a postgraduate specialization in pharmaceutical medicine, and is board certified by the UK General Medical Council in pharmaceutical medicine.
SPRUCE BIOSCIENCES, INC. Chief Executive Officer Javier B. Szwarcberg acquired 266 shares of common stock at $4.5305 per share through the company’s 2020 Employee Stock Purchase Plan. This grant increased his direct holdings to 19,270 shares, reflecting routine compensation-related share accumulation rather than an open-market trade.
Spruce Biosciences director Daniel K. Spiegelman received a grant of stock options for 1,700 shares of Common Stock. The options have an exercise price of 52.7000 per share and expire on May 20, 2036. Following this grant, he holds 1,700 derivative securities directly.
The options vest on the first anniversary of the grant date, with full vesting no later than the company’s 2027 annual stockholder meeting, subject to his continuous service under the 2020 Equity Incentive Plan. The award will also vest in full upon a Change in Control as defined in that plan.
Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.
SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.
Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.
The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.
Spruce Biosciences director Keli Walbert received a new stock option grant. The Form 4 shows an award of 1,700 stock options for common stock at an exercise price of $52.70 per share, with 1,700 derivative securities held after the transaction.
The options vest on the first anniversary of the grant date and will in any case be fully vested by the company’s 2027 annual stockholder meeting, subject to continuous service. They also vest in full upon a change in control. This is a compensation-related grant, not an open-market purchase or sale.